2,6-Diamino-4,5,6,7-tetrahydrobenzothiazole

We are 2,6-Diamino-4,5,6,7-tetrahydrobenzothiazole CAS:104617-49-4 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name: 2,6-Diamino-4,5,6,7-tetrahydrobenzothiazole
CAS.NO:  104617-49-4
Synonyms:
7-tetrahydrobenzothiazole
6-DiaMino-4
4,5,6,7-TETRAHYDRO-1,3-BENZOTHIAZOL-2,6-DIAMINE
4,5,6,7-Tetrahydrobenzo[d]thiazole-2,6-diamine
4,5,6,7-tetrahydro-2,6-benzothiazole diamine
4,5,6,7-Tetrahydro-2,3-Benzothiazole Diamine

Molecular Formula: C7H11N3S
Molecular Weight:  169.24700

Physical and Chemical Properties:
Density: 1.313 g/cm3
Boiling point: 359ºC at 760 mmHg
Melting point: /
Flash point: 170.9ºC
Refractive index: 1.655

Specification:
Appearance: Almost white or light gray powder
Purity:≥99%
Related substance:≤0.5%
Residue on ignition:≤0.5%
Heavy metals:≤0.002%
Water content:≤1.0%

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage: Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:
Intermediates of Pramipexole CAS:104632-26-0
Intermediates of Pramipexole dihydrochloride CAS:104632-25-9

2,6-Diamino-4,5,6,7-tetrahydrobenzothiazole


Related News: Beta Bionics is committed to obtaining regulatory approval and commercializing all three iLet configurations.4-[6-amino-2-(4-cyanoanilino)pyrimidin-4-yl]oxy-3,5-dimethylbenzonitrile The Company’s immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA.40665-68-7 The Company’s immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA.4-Fluorobutanol CAS:61599-24-4 The Company’s immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA.The Company’s immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA.

Related Products
Product Name
Fmoc-N-Me-D-Leu-OH View Details
2-Chlorophenol View Details
dimethyl 2-(4-bromophenyl)propanedioate View Details
1-Bromo-3-methoxypropane manufacturer (3R)-3-<(tert-Butyldimethylsilyl)oxy>pentanedioic acid 1-<(R)-mandelic acid> ester manufacturer 4-Fluoro-3-(trifluoromethyl)phenol manufacturer Dibromomethane manufacturer 1-((4-Aminobenzenemethane)sulfonyl)pyrrolidine manufacturer